Effect of Plant Stanol Ester-Containing Spread on Estimated Cardiovascular Risk in Comparison to Mediterranean Diet
NCT ID: NCT00793364
Last Updated: 2009-05-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
150 participants
INTERVENTIONAL
2008-11-30
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Duration: 16 weeks (4 weeks of lifestyle advice and 12 weeks of treatment).
Prespecified analyses:
1. Postmenopausal women vs women with child bearing potential.
2. Older (\>65 years of age) vs younger subjects,
3. Subjects with impaired fasting glucose levels.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stanol ester
Stanol-ester administration group
Stanol ester spread
Stanol ester spread 20 g every day
Placebo spread
Placebo spread group
Placebo spread
Placebo spread 20 g every day
Mediterranean diet group
Mediterranean diet group
Mediterranean Diet
Mediterranean Diet every day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Stanol ester spread
Stanol ester spread 20 g every day
Placebo spread
Placebo spread 20 g every day
Mediterranean Diet
Mediterranean Diet every day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Established CVD (coronary heart disease, peripheral arterial disease, aortic aneurysm, or symptomatic carotid artery disease) or T2DM
* Chronic diseases (including liver diseases)
* Pregnancy
* Malignancies
* Unwillingness to participate
45 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Minerva SA
INDUSTRY
Hellenic Atherosclerosis Society
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hippocration Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vasilios G Athyros, MD
Role: PRINCIPAL_INVESTIGATOR
Hippocration Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aristotelian University, Hippocration Hospital
Thessaloniki, , Greece
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Nguyen TT, Dale LC, von Bergmann K, Croghan IT. Cholesterol-lowering effect of stanol ester in a US population of mildly hypercholesterolemic men and women: a randomized controlled trial. Mayo Clin Proc. 1999 Dec;74(12):1198-206. doi: 10.4065/74.12.1198.
Athyros VG, Kakafika AI, Papageorgiou AA, Tziomalos K, Peletidou A, Vosikis C, Karagiannis A, Mikhailidis DP. Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors. Nutr Metab Cardiovasc Dis. 2011 Mar;21(3):213-21. doi: 10.1016/j.numecd.2009.08.014. Epub 2009 Nov 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
171108
Identifier Type: -
Identifier Source: secondary_id
MINERVA 01
Identifier Type: -
Identifier Source: org_study_id